"Exploring the Potential Benefits of Using Dapagliflozin in Cirrhotic Chronic Liver Disease Patients- A Randomized Controlled Trial"

Summary

This study aims to evaluate beneficial effects of using dapagliflozin in cirrhotic chronic liver disease patients. We hypnotized that the use of dapagliflozin will be associated with fewer need for large volume paracentesis hence better control of ascites, fewer need for ICU admissions, improvement of patient quality of life, better healthcare cost saving and reduced mortality rate.

Eligibility

Inclusion Criteria:

* Adult patients 18 years of age and older with a diagnosis of liver cirrhosis with any degree of ascites that led to previous or recent hospital admission (determined by clinical findings and imaging) will be included in the study.

Exclusion Criteria:

1. Child Pugh score ≥ 12 or MELD score \> 25.
2. Previous history of hypoglycemia or has a previous history of DKA.
3. Blood pressure less than 90/60 or need dose of midodrine \>15 mg/day.
4. Previous history of recurrent urinary tract infections (more than 2 infections in the last 6 months) or anatomic urologic defects that predispose to urinary tract infection.
5. Pregnant or lactating female patients.
6. Hypersensitivity to dapagliflozin.
7. eGFR \< 30 ml/min/1.73 m2
8. Had hepatocellular carcinoma or any malignancy.
9. Serum sodium level \< 125 mg/dl.
10. Portal vein thrombosis.

Conditions2

Interventions1

Related trials

• CardioPROTECTion with Dapagliflozin in Breast Cancer Patients Treated with AnthrAcycline - PROTECTAA TRIAL — 4th Military Clinical Hospital with Polyclinic, Poland
• Dapagliflozin in Depression — Tanta University
• Effect of the Use of Dapagliflozin in Patients With Refractory Heart Failure — Fundación para la Investigación del Hospital Clínico de Valencia
• Efficacy of Dapagliflozin Versus Metformin in Polycystic Ovary Syndrome — Future University in Egypt
• Pleiotropic Effects of Dapagliflozin in Patients With Acute Coronary Syndromes — University of Sao Paulo
• SGLT2 Inhibitors As First Line Therapy to Prevent Renal Decline in Type 2 Diabetes — The George Institute
• A Phase III Study to Investigate the Efficacy and Safety of Elecoglipron Alone or in Combination With Dapagliflozin Compared With Placebo in Adults With Type 2 Diabetes Mellitus — AstraZeneca
• A Phase III Study to Investigate the Efficacy and Safety of the Combination of Elecoglipron and Dapagliflozin in Adults With Type 2 Diabetes Mellitus — AstraZeneca

Browse More Trials